News

Biocon acquires OCRPS of Biocon Biosphere, Biocon Pharma for ₹315 croreShares of Biocon Ltd ended at ₹389.90, up by ₹0.15, or 0.038%, on the BSE.By Jomy Jos Pullokaran  March 4, 2026, 1:06:55 AM IST (Published)2 Min ReadBiotech firm Biocon Ltd on Tuesday (March 3) said it has completed the acquisition of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) of its wholly owned subsidiaries.

The company acquired 11.53 crore OCRPS of ₹10 each of Biocon Biosphere Ltd at a total cost of ₹115.34 crore, comprising ₹20 crore in cash and ₹95.34 crore, including earlier loans and accrued interest. Biocon Biosphere, incorporated in 2019, manufactures APIs and generic formulations through its greenfield facilities in Vizag and Bengaluru. Its turnover for FY24-25 was ₹13 crore.

Biocon also acquired 20 crore OCRPS of ₹10 each of Biocon Pharma Ltd at a cost of ₹200 crore in cash. Biocon Pharma, incorporated in 2014, develops and manufactures generic formulations for global markets, including the US and Europe, with an oral solid dosage facility in Bengaluru. Its turnover for FY24-25 was ₹982.5 crore.

Also Read: Biocon shares in focus after announcing Biologics unit buyout, fund raise approval

Both transactions are related-party transactions as they involve wholly owned subsidiaries, but are exempt under SEBI Listing Regulations. The investments are intended to support ongoing business requirements, including working capital, capex, and general corporate needs.

Following the acquisition, Biocon holds 100% of the paid-up share capital, including equity shares and OCRPS, of both subsidiaries.

Third Quarter Results

Net profit came in at ₹143.8 crore, below the CNBC-TV18 poll estimate of ₹167.5 crore, but sharply higher than ₹25.1 crore reported in the year-ago quarter. The company recorded a one-time exceptional loss of ₹293.4 crore during the quarter.

Also Read: Biocon Biologics sees strong FY27 as new biosimilars gain traction

Revenue stood at ₹4,173 crore, missing the estimate of ₹4,556.2 crore, though it grew 9.2% from ₹3,821 crore a year earlier. EBITDA rose 11% year-on-year to ₹833.6 crore from ₹751 crore, but fell short of the estimated ₹923.7 crore. EBITDA margin was 20%, marginally below the 20.3% estimate, compared with 19.7% in the corresponding quarter last year.

Shares of Biocon Ltd ended at ₹389.90, up by ₹0.15, or 0.038%, on the BSE.Continue Reading(Edited by : Jomy Jos Pullokaran)TagsBioconshare market today